FORM PTC-1449 (Modified) US DEPARTMENT OF COMMERCE Docket No Application No 09/704,212 Approved for use through 10/31/2002 50623.71 INFORMATION DISCLOSURE CITATION Applicant Wouter E. Roorda et al. in an Application Group Art Unit Filing Date (Use several sheets if necessary) 1772 10/31/00 PRIENT DOCUMENTS U.S. Filing Date if Subclass Date of Ref. No **Document** Examiner Appropriate Initial Number Patent 335.5 128 2,072,303 3/2/37 Herrmann et al. 264 288 3,953,566 4/27/76 Gore Eriksson et al. 424 183 10/3/78 А3 4,118,485 2/5/80 Gore 174 102 Α4 4,187,390 Scantlebury et al. 433 173 7/30/85 Α5 4,531,916 Teng 3/31/87 514 56 A6 4,654,327 Α7 Hiroyoshi 623 1 4,678,468 7/7/87 56 Griffin et al. 514 **8**A 4,745,105 5/17/88 56 Α9 4,745,107 5/17/88 Foley et al. 514 266 Hsu et al. 604 A10 4,871,357 10/3/89 604 266 A11 4,895,566 1/23/90 Lee 128 772 12/18/90 Ofstead A12 4,977,901 5/7/91 Solomon et al. 514 56 A13 5,013,717 9/10/91 Hsu 604 266 A14 5,047,020 Solomon et al. 523 100 A15 10/29/91 5,061,738 A16 5,069,899 12/3/91 Whitbourne et al. 424 56 604 265 A17 5,135,516 8/4/92 Sahatjian et al. A18 5,181,903 1/26/93 Vann et al. 600 36 Walder et al. 264 171 A19 5,322,659 6/21/94 7/12/94 A20 Slepian 604 101 5,328,471 A21 De Goicoechea et al 623 1 5,383,927 1/24/95 78.27 Hsu et al. 424 A22 5/23/95 5,417,969 2.3 A23 5,441,759 8/15/95 Crouther et al. 427 427 2.30 A24 5,464,650 11/7/95 Berg et al. 423 A25 424 5,525,348 6/11/96 Whitbourne et al. EXAMINER DATE CONSIDERED EXAMINER Initial if references considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered nclude copy of this form with next communication to applicant

FORM PTC-1449 (Modified) US DEPARTMENT OF COMMERCE Docket No Application No. 09/704,212 50623.71 Approved for use through 10/31/2002 US Patent and Trademark Office INFORMATION DISCLOSURE CITATIONA Applicant Wouter E. Roorda et al. in an Application Filing Date Group Art Unit (Use several sheets if necessary) JUN 1 3 2002 1772 10/31/00 U.S. WATENT DOCUMENTS PADEMARY Filing Date if Name Subclass Examiner Ref. No **Document Appropriate** Patent Number 514 56 A26 7/30/96 Hsu et al. 5,541,167 198 A27 10/7/97 Bley et al. 606 5,674,241 A28 11/26/96 Haimovich et al. 623 1 5,578,073 424 423 A29 5,605,696 2/25/97 Eury et al. A30 5,628,730 5/13/97 Shapland et al. 604 21 424 9.411 A31 Greff et al. 5,667,767 9/16/97 A32 5,670,558 9/23/97 Onishi et al. 523 112 623 A33 5,700,286 12/23/97 Tartaglia et al. 514 Hunter et al. 449 A34 5,716,981 2/10/98 9/1/98 Racchini 604 96 A35 5,800,392 623 1 A36 5,824,049 10/20/98 Ragheb et al. 604 49 A37 5,830,178 11/3/98 Jones et al. Ding et al. 427 2.21 A38 11/17/98 5,837,313 A39 12/22/98 Greff et al. 424 9.411 5,851,508 2/2/99 Tuch 604 265 A40 5,865,814 623 1 A41 5,873,904 2/23/99 Ragheb et al. 3/2/99 Lunn 623 1 A42 5,876,433 422 A43 5,879,697 3/9/99 Ding et al. 424 10/26/99 604 A44 5,971,954 Conway et al. 96 427 A45 5,980,928 11/9/99 Terry 424 11/9/99 Ding 427 2.24 A46 5,980,972 264 127 A47 5,955,016 9/21/99 Goldfarb A48 5,968,070 10/19/99 Bley et al. 606 5.993.489 11/30/99 628 A49 Lewis et al. EXAMINER DATE CONSIDERED 22/02 EXAMINER. Initial if references considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformation of the confor nclude copy of this form with next communication to applicant

FORM PTC-1449 (Modified) Application No. US DEPARTMENT OF COMMERCE Docket No. 09/704,212 50623.71 Approved for use through 10/31/2002 INFORMATION DISCLOSURE CITATION & Applicant Wouter E. Roorda et al. in an Application Group Art Unit (Use several sheets if necessary) Filing Date JUN 1 3 2002 10/31/00 1772 U.S. WATENT DOCUMENTS Subclass Filing Date if Class Examiner Ref. No **Document** Date of Name **Appropriate** Number Patent Marchant et al. 427 2.3 8/15/97 450 5,993,890 11/30/99 5/16/96 623 1 451 6.096.070 8/1/00 Ragheb et al 2/18/98 1 623 A52 6,010,530 1/4/00 Goicoechea 424 1.25 11/3/97 1/18/00 Greff et al. A53 6.015.541 11/1/96 A54 6,048,484 4/11/00 House et al. 264 322 2/16/99 7/18/00 Tu et al. 623 1 6.090.134 A55 427 2.3 4/19/99 6,153,252 11/28/00 Hossainy et al. A56 6/28/99 457 12/26/00 Dereume et al. 623 1.13 6,165,212 FOREIGN PATENT DOCUMENTS Subclass Translation Class Ref. No. Date of Country Examiner Document **Publication** Initial Number Yes 2MΊВ1 EP 0665023 8/2/95 European B2 EP 0970711 1/12/00 European **PCT** В3 WO91/12846 9/5/91 WO97/45105 12/4/97 PCT **B**4 PCT B5 WO99/63981 12/16/99 3/9/00 PCT B6 WO00/12147 11/2/00 PCT **B**7 WO00/64506 1/11/01 **PCT** WO01/01890 B8 6/28/01 **PCT** В9 WO01/45763 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Adams et al., Physical Chemistry of Surfaces, 6th Ed., Chapter XIII, pp. 465-499, Wiley Barath et al., Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation C2 Endothelial Injury, JACC 13(2):252A (1989) (Abstract). Chen et al., Boundary Layer Infusion of Heparin Prevents Thrombosis and Reduces Neoipti C3 Hyperplasia in Venous Polytetrafluoroethylene Grafts Without Systemic Anticoagu 22(3):237-247 (Sept. 1995) DATE CONSIDERED EXAMINER 2/02 EXAMINER Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered include copy of this form with next communication to applicant

FORM PTG-1449 (Modified)						Docket No.		Application No.
	_	mrough 10/31/2002		nt and Trademar			50623.71	09/704,212
INFORMATION DISCLOSURE CITATION F Applicant in an Application Wouter E. R								oorda et al.
		(Use several sheets	f necessary)	JUN 1 3	2002	Filing Date	10/31/00	Group Art Unit 1772
		OTHER DO	CUMENT	Including	Ayıtayır,	Title, Date	e, Pertinent Pages, et	c.)
C4 Matsumaru et al., E Polymer Edn. 8(7):			mbolic Materials for Endovascular Treatment of Cerebral Lesions, J. Biomater. Sci. 555-569 (1997).					
	C5	Miyazaki et al , Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice, Chem. Pharm. Bull. 33(6):2490-2498 (1985).						
	C6	Miyazawa et al., Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat, J. Cardiovasc. Pharmacol. 30(2):157-162 (1997).						
	C7	Ohsawa et al., Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty, Am. Heart J. 136(6):1081-1087 (Dec. 1998).						
	C8	Shigeno, <i>Prevention of Cerebrovascular Spasm by Bosentan, Novel Endothelin Receptor</i> , Chem. Abstracts 125 212307 (1996).						
	C9	Silver et al., Biomaterial Science and Biocompatibility, pp. 19-26, Springer-Verlag (1999).						
V	C10	Woebcken, International Plastics Handbook: For the Technologist, Engineer, and User, 3 Ed., Eds. Hain and Hyatt, pp. 234-240, Hanser/Gardner (1995).						
	C11							
	C12							
	C13			-				
	C14							
	C15			A 764-4			70.01	
	C16		,				14.	
	C17							
	C18				400		7%	
	C19							
	C20							
	C21		, .					
	C22					*		
	C23							
	C24							
	C25		1					
	C26							
	C27							
EXAMINER _	Jen	mifer Kall	, Mich	nénét	ATE CONS	SIDERED	5/22/6:2	
		nces considered, whether or th next communication to ap	not citation is in		MPEP § 6	09; Draw line	through citation if not in cor	formance and not considered.